slides · global inventory
Turn
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 37,461
Current window 22,141-22,170
Pages 1,249
Rows per page 30
Beat
22,141-22,170 of 37,461
19
The slide highlights the cost and structure of subordinated debt as a component of the holding company's capital stack.MainStreet Bancshares | Results Presentation Deck | 31 slides · MainStreet Bancshares, Inc.
Conference presentation Investor relations Beat · Satisfaction1 hit
20
Data is YTD as of 9/30/22.MainStreet Bancshares | Results Presentation Deck | 31 slides · MainStreet Bancshares, Inc.
Conference presentation Investor relations Beat · Satisfaction1 hit
12
Matinas BioPharma | Investor Presentation Deck | 31 slidesMatinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Solution1 hit
08
The slide serves as a title or introductory page for a specific drug candidate.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
09
Includes definitions of acronyms and citations for preclinical studies.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
10
Study methodology involves 10-week treatment on high fat/fructose/CHO diet.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
11
Study design timeline included; statistical significance noted for treatment groups.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
12
Includes definitions for abbreviations and source citations.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
13
NASH (Non-Alcoholic Steatohepatitis); NAFLD (Non-Alcoholic Fatty Liver Disease); T2DM (Type 2 Diabetes Mellitus); FPFV (First Patient First Visit); LPLV (Last Patient Last Visit).NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
14
Company branding slide for a specific drug candidate.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
15
The slide uses a hub-and-spoke diagram to illustrate the systemic effects of oxyntomodulin.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
16
Data from preclinical study in HF-DIO mice.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
17
The slide highlights that DA-1726 efficacy is likely due to dual GLP1R/GCGR agonism.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
18
Study uses male DIO-NASH mice with 30-week GAND feeding and 9-week treatment regimen.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
19
Includes study methodology timeline and statistical significance markers.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
20
NASH (Non-Alcoholic Steatohepatitis); MAD (Multiple Ascending Dose); SAD (Single Ascending Dose); PK (Pharmacokinetic); PD (Pharmacodynamic); FPFV (First Patient First Visit); LPLV (Last Patient Last Visit).NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
07
The slide uses a list of icons to represent key clinical attributes of the drug candidate.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
07
The slide uses a four-column layout to describe the biological composition of each product.Organicell Regenerative Medicine | Investor Presentation Deck | 17 slides · Organicell Regenerative Medicine
Pitch deck Investor relations Beat · Solution1 hit
10
The chart includes a trend line annotation showing a 33% decline from Q3 '21 to Q3 '22.Overstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Satisfaction1 hit
11
The chart displays a dual-axis view of gross margin performance over time.Overstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Satisfaction1 hit
12
The chart uses a combination of bar (absolute $) and line (percentage) to show trends.Overstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Satisfaction1 hit
13
The chart highlights a decline in both absolute EBITDA and margin percentage over the two-year period.Overstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Satisfaction1 hit
14
The chart combines a bar chart for active customers and a line chart for order frequency.Overstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Satisfaction1 hit
15
The chart displays a decline in order volume alongside an increase in average order value.Overstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Satisfaction1 hit
16
The slide uses a before-after framing to isolate the impact of 'non-home only' customers on overall performance metrics.Overstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Satisfaction1 hit
17
The slide uses a clear layout to contrast balance sheet status with specific capital allocation activities.Overstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Satisfaction1 hit
14
The slide uses a biological process diagram to explain the drug's mechanism.PaxMedica | Investor Presentation Deck | 24 slides · PaxMedica
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
15
Includes a medical illustration of the intranasal drug delivery pathway to the brain.PaxMedica | Investor Presentation Deck | 24 slides · PaxMedica
Pitch deck Investor relations Beat · Solution1 hit
15
Includes detailed footnotes regarding non-GAAP adjustments and specific accounting provisions.Regions Financial Corporation | Results Presentation Deck | 38 slides · Regions
Conference presentation Investor relations Beat · Satisfaction1 hit
16
Includes footnotes regarding data definitions for digital sales and transactions.Regions Financial Corporation | Results Presentation Deck | 38 slides · Regions
Conference presentation Investor relations Beat · SatisfactionLoop · Zoom In1 hit